Shopping Cart
- Remove All
- Your shopping cart is currently empty
GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $44 | In Stock | |
5 mg | $97 | In Stock | |
10 mg | $163 | In Stock | |
25 mg | $270 | In Stock | |
50 mg | $432 | In Stock | |
100 mg | $693 | In Stock | |
500 mg | $1,560 | In Stock |
Description | GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively). |
Targets&IC50 | LXRβ:7.4(pic50), LXRα:7 (pic50) |
In vitro | GSK2033 dose-dependently inhibits basal transcription in full-length LXRα or full-length LXRβ cotransfection assays (IC50s: 17 nM and 9 nM, respectively). GSK2033 also effectively inhibits the transcription of an ABCA1 driven luciferase reporter dose-dependently (IC50s: 52 nM for LXRα and 10 nM for LXRβ). GSK2033 also suppresses the expression of both of fatty acid synthase (FASN) and SREBP1[2]. |
In vivo | GSK2033 (one month) treatment, does not have obviously effects on hepatic triglyceride levels. GSK2033 treatment also have no effects on plasma triglyceride levels[2]. |
Molecular Weight | 591.66 |
Formula | C29H28F3NO5S2 |
Cas No. | 1221277-90-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: <1 mg/mL (insoluble or slightly soluble), Sonication and heating are recommended. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.